TCM
NVIV

Teza Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Teza Capital Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed -$124K – 632
2016
Q4 		$124K Buy
+2
New +$179K 0.17% 196

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Teza Capital Management's NVIV Position: Q1 2017 in Review

Teza Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2017, closing a stake of 2 shares — an estimated $124K sold.

Teza Capital Management first reported a position in NVIV in Q4 2016 and held it in 1 quarter. The position peaked at $124K in Q4 2016. 42 funds tracked by Wall St. Rank hold NVIV as of Q1 2017.

  • Teza Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 2 InVivo Therapeutics Holdings Corp shares in Q1 2017, an estimated $124K.
  • Teza Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's InVivo Therapeutics Holdings Corp position peaked at $124K in Q4 2016.
  • 42 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.